Enovis Corporation Common Stock (ENOV)
Healthcare › Orthopedic, Prosthetic & Surgical Appliances & Supplies
Price History
Feb 9, 2026 — Aug 9, 2026Investment Snapshot
- P/B of 1.04 — trading near book value
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -41.8%
- Revenue growing at 7% annually
Enovis Corporation Common Stock (ENOV) is a Healthcare company operating in Orthopedic, Prosthetic & Surgical Appliances & Supplies, listed on the NYSE , with a market capitalisation of $1.5 billion . Key value metrics: P/B ratio 1.04, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Enovis Corporation Common Stock — Fundamental Analysis Summary
On financial health, ENOV shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -41.8% (sector average: -20.1%), and manageable leverage with a debt-to-equity ratio of 0.87.
StockPik's composite Value Score for ENOV is 70/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ENOV reports a high gross margin of 60.7% (sector average: 37.4%) and a negative operating margin of -24.1%.
ENOV shows revenue growing at 7% year-over-year, with earnings declining at 43%.